Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 27 February 2018, 09:33 HKT/SGT
Share:
    

Source: Eisai
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Jointly Developed by Eisai and Saint-Plus

TOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today.

According to the Ministry of Health, Labour and Welfare, the number of people with dementia was approximately 4.62 million in 2012, and is expected to increase to approximately 7 million by 2025. According to a survey on dementia conducted by Eisai of 224 men and women aged 40 and older, the highest source of anxiety was "personal or family member's incidence of dementia" followed by "burden of nursing care on family" and "financial burden caused by dementia care," while the top three factors for reducing anxiety were "consulting with healthcare and nursing care professionals, the government and other organizations," "preparing savings and other finances" and "obtaining information on preventing dementia."

Eisai and Saint-Plus entered into a joint development agreement for insurance that aims to reduce anxiety over dementia in December 2016, and jointly developed "Dementia Support" small amount short-term insurance to provide for dementia. For beneficiaries aged 40 to 90, submitting an application is possible with a simple notice even after becoming certified as requiring long-term care and beneficiaries receive a lump-sum payment upon diagnosis of specific conditions such as organic dementia. In addition, as ancillary services, policyholders and beneficiaries may be provided with various kinds of useful information on dementia as well as introduced to services including telephone consultation services operated by the non-profit organization Alzheimer's Association Japan about matters such as symptoms of dementia and concerns about nursing care.
The sale of insurance, including provision of ancillary services, is handled by Saint-Plus, and Eisai receives royalties relating to joint development.

About "Dementia Support" Insurance to Provide for Dementia

Sales of "Dementia Support" insurance are conducted by Saint-Plus.
1. Provides assurance against organic dementia
2. Submitting an application is possible even after becoming certified as requiring long-term care
3. A medical certificate is not required from a physician, it is possible to apply with just a simple notice
4. There are three courses for benefit payments
5. Insurance premiums start from 163 yen per month (60 year old male: 200,000 yen rider course)
6. People aged 40 years old up to and including people aged 90 years old may apply
7. It is possible to continue up to age 100 by renewing the policy

Saint-Plus' website for product information: https://www.saint-plus-ins.co.jp/sasae/ (available in Japanese only)

For inquiries about the product, please contact Saint-Plus: 0120-786-765 (Weekdays 9:30 to 17:00, excluding Saturdays, Sundays, public holidays, the New Year and other holiday periods, for residents in Japan only)

About Saint-Plus Small Amounts and Short Term Insurance Co., Ltd.

The Saint-Care Group, which provides comprehensive health care services, hears the voices from the field of nursing care and welfare, and in wanting to provide a "new support framework" that will be useful to those who truly need nursing care and their families, Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. developed and markets Japan's first private nursing care insurance as a nursing care business.

For more information about Saint-Plus Small Amounts and Short Term Insurance Co., Ltd., please visit https://www.saint-plus-ins.co.jp/ (available in Japanese only)


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Feb 27, 2018 09:33 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 20, 2018 17:50 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Apr 19, 2018 11:07 HKT/SGT
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Apr 13, 2018 13:22 HKT/SGT
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
Apr 2, 2018 12:44 HKT/SGT
Eisai Submits Supplemental New Drug Application to U.S. FDA
Mar 28, 2018 18:33 HKT/SGT
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Mar 23, 2018 14:41 HKT/SGT
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Mar 23, 2018 13:40 HKT/SGT
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: